Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: A retrospective study in patients undergoing primary percutaneous coronary intervention

Clinical Therapeutics

Volumn 28, Issue 11, 2006, Pages 1812-1819

  Ishii, Hideki ^a,b   Ichimiya, Satoshi ^b   Kanashiro, Masaaki ^b   Aoyama, Toru ^a,b   Ogawa, Yasuhiro ^a   Murakami, Ryuichiro ^a   Amano, Tetsuya ^a   Naruse, Keiko ^c   Matsubara, Tatsuaki ^c   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Yokkaichi Municipal Hospital   (Japan)

^c AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

acute myocardial infarction; percutaneous coronary intervention; statin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICORANDIL; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; COVARIANCE; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENZYME BLOOD LEVEL; FEMALE; HAZARD RATIO; HEART MUSCLE REPERFUSION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RETROSPECTIVE STUDIES;

EID: 33845988074     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.11.003     Document Type: Article

References (24)

1. [published correction appears in N Engl J Med. 1997;337:287]. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO Ilb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med. 336 (1997) 1621-1628
2. [published correction appears in JAMA. 1998;279: 1876]. Weaver W.D., Simes R.J., Betriu A., et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 278 (1997) 2093-2098
3. Herrmann J., Lerman A., Baumgart D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation. 106 (2002) 2180-2183
4. Briguori C., Colombo A., Airoldi F., et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J. 25 (2004) 1822-1828
5. Mulukutla S.R., Marroquin O.C., Smith C., et al. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of peripro-cedural myocardial injury. Am J Cardiol. 94 (2004) 1363-1366
6. Pasceri V., Patti G., Nusca A., et al., ARMYDA Investigators. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
7. Iwakura K., Ito H., Kawano S., et al. Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J. 27 (2006) 534-539
8. Ishii H., Ichimiya S., Kanashiro M., et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with STsegment-elevation myocardial infarction. Circulation 112 (2005) 1284-1288
9. van't Hof A.W., Liem A., de Boer M.J., Zijlstra F., and Zwolle Myocardial Infarction Study Group. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 350 (1997) 615-619
10. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
11. [published correction appears in Acta Physiol Scand. 2002;174:85]. Jones S.P., and Lefer D.J. Card ioprotective actions of acute HMG-CoA reductase inhibition in the setting of myo cardial infarction. Acta Physiol Scand. 173 (2001) 139-143
12. Lefer A.M., Campbell B., Shin Y.K., et al. Simvastatin preserves the ischemic reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 (1999) 178-184
13. Bell R.M., and Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid low ering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol. 41 (2003) 508-515
14. Rosenson R.S., and Tangney C.C. Antiatherothrombotic properties of statins: Implications for cardiovas cular event reduction. JAMA 279 (1998) 1643-1650
15. Ledoux S., Laouari D., Essig M., et al. Lovastatin enhances ecto-5′-nucleotidase activity and cell surface expression in endothelial cells: Implication of rho-family GT-Pases. Circ Res 90 (2002) 420-427
16. Kitakaze M., Hori M., Morioka T., et al. Alpha 1-adrenoceptor activation mediates the infarct size-limiting effect of ischemic preconditioning through ugmentation of 5′-nucleotidase activity. J Clin Invest 93 (1994) 2197-2205
17. Sanada S., Asanuma H., Minamino T., et al. Optimal windows of statin use for immediate infarct limitation: 5′-Nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110 (2004) 2143-2149
18. Aikawa M., Sugiyama S., Hill C.C., et al. Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106 (2002) 1390-1396
19. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metal loproteinases, and cell death in human carotid plagues: Implications for plaque stabilization. Circulation 103 (2001) 926-933
20. Tanaka A., Kawarabayashi T., Nishibori Y., et al. No-reflow phenomenon and lesion morphology in patients with acute myocardial infarction. Circulation 105 (2002) 2148-2152
21. Mensah K., Mocanu M.M., and Yellon D.M. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten?. J Am Coll Cardiol 45 (2005) 1287-1291
22. Ichihara K., Satoh K., and Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase in hibitors, on myocardial stunning in dogs. J Cardiovasc Pharmacol 22 (1993) 852-856
23. Satoh K., and Ichihara K. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. J Cardiovasc Pharmacol 35 (2000) 256-262
24. Ichihara K., and Satoh K. Disparity between angiographic regression and clinical event rates with hydropho bic statins. Lancet 359 (2002) 2195-2198